Biosketches of Awardees

ISAM Awards 2006 and 2005
ISAM AWARDS 2011 Awarded at the 18th International Congress in Rotterdam, The Netherlands
Career Achievement Award
	Dr. A. Bruce Montgomery. Dr. Montgomery is the CEO of Cardeas Pharma. Prior to founding Cardeas, he was a SVP of Gilead Sciences from 2006 to 2010. Prior to sale to Gilead, Bruce was the Founder and CEO of Corus Pharma of Seattle. Until October 2000, Dr. Montgomery served as EVP of R and D at PathoGenesis Corporation that was acquired by Chiron. Dr. Montgomery has extensive pharmaceutical company experience in drug development, operations and financing. Dr. Montgomery has been responsible for three complete drug approvals, aerosolized pentamidine, tobramycin solution for inhalation, aztreonam lysine for inhalation (the only three FDA approved inhaled antimicrobials); from patent filings to advisory board presentations. From 1985 to 1989, Dr Montgomery was co inventor, and then led the effort to obtain FDA approval of aerosolized pentamidine, the second AIDS drug approved by the FDA. While at Genentech between 1989-1993, he started multiple other programs that have led to three other FDA approvals including Pulmozyme, Xolair and Raptiva. Dr. Montgomery received his Bachelor of Science in Chemistry in 1975 (Magna cum Laude, Outstanding Chemistry Major (Merck Award)), and Doctorate of Medicine in 1979 (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. Dr. Montgomery is a board certified internist and pulmonologist.
Thomas T. Mercer Award (jointly sponsored with AAAR)
	Dr. Yung Sung Cheng is a Senior Scientist and Director of the Aerosol and Respiratory Dosimetry Program at Lovelace Respiratory Research Institute. His research interests are centered in the following areas: aerosol drug delivery; generation and characterization of aerosols including bioaerosols; deposition in the respiratory tract; air quality of ambient, occupational and indoor environments; measurement of radon and radon progeny; and inhalation toxicology. He has been involved in design and evaluation of air sampling instruments for radioactive aerosol and biological agents using aerosol wind tunnel and BSL laboratory. He has also involved in many field studies to assess human exposure to toxic aerosols and industrial effluents as well as to verify performance of bio-detector in the field. More recently, he has been conducting studies on aerosol deposition and health effects of nanomaterial and fibers. Dr. Cheng has published over 270 papers on aerosol science, lung deposition and pharmaceutical drug delivery in peer-reviewed journals and book chapters. He was an Associate Editor of the journal of Aerosol Science and Technology and is on the editorial board of Aerosol and Air Quality Research. Dr. Cheng is a fellow of the American Association for Aerosol Research.
Young Investigator Award
	Laurent Vecellio is the Scientific Director of Aerodrug at DTF Medical (Diffusion Technique Française, Saint Etienne, France). He works also as associated researcher for the National Institute for Health and Medicine (INSERM) in the Pr Patrice Diot laboratory at University of Tours in France. He is currently involved in 14 projects for industrial and academics partners. He studied physical engineering in the University of Paris XII with Pr André Renoux about a special topic on basic aerosol science and he obtained his degree in 1999. He supported his thesis about aerosols in medicine within the Pr Patrice Diot laboratory (Tours University) and he received his PhD in 2002 with honours and his accreditation to supervise university research in 2007. He obtained the Bricard award in 2002 from the French Aerosol association (ASFERA). His past research interests have included the metrology of medicine aerosols, particularly to measure efficiently nebulizers performances in terms of particle size and output. Based on these in vitro methods, he developed jet nebulizers and optimized mesh nebulizer performances for lung diseases treatment. He compared aerosol prediction deposition to in vivo results using radioscintigraphy techniques and drug assay in animals and humans. He performed basic and clinical studies for evaluating new nebulized drugs for CF, lung cancer and ventilated patients. His Current work also involves the determination of new physical parameters to predict aerosol deposition, particularly real time measurement. More recently he has been involved in the nasal drug deposition and in research on aerosol of nanoparticles.
Student Research Award
	Mohanad Naji Sahib received his B.Sc. and M.Sc. in Pharmaceutics from the University of Baghdad, Iraq in 1999 and 2006, respectively. He is completing his PhD. under the supervision of Dr. Yvonne Tze Fung Tan in the research group of pulmonary delivery system, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Mohanad worked on the formulation and development of self-associated nanomicelles (SSMs) loaded with a poorly soluble corticosteroid, budesonide (BUD). He examined the physicochemical and aerodynamic characterisations of the SSMs. In addition, the pharmacodynamic evaluation of the SSMs was carried out using sensitised asthmatic rats. The results showed that the deposition patterns using different nebulisers, in vitro dissolution profiles and pharmacodynamic durations of the formulated SSMs were more superior than some of the marketed products. The same SSM system was also applied to another corticosteroid, similar encouraging results were obtained. This SSM system showed a great potential in the treatment of asthma and other airway inflammatory diseases.
Juraj Ferin Award (for outstanding contributions to ISAM)
	Beth L. Laube holds a Ph.D. from the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland and is currently Professor of Pediatrics at the Johns Hopkins School of Medicine. Dr. Laube is a past-President of the International Society for Aerosols in Medicine (ISAM) and serves on the Editorial Board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery. From 2003-2007, she represented ISAM on the advisory committee to the World Health Organization Product Development Group for the Aerosolized Measles Vaccine Project. Together with 10 co-authors representing ISAM and the ERS, she recently published the findings of an ERS/ISAM Joint Task Force that was convened to advise the pulmonary specialist as to what they should know about the new inhalation therapies. She is currently working with a subcommittee of ISAM’s Regulatory Networking Group to publish guidelines that will standardize lung imaging techniques for aerosol deposition. Dr. Laube’s research involves in vivo quantification of the deposition and removal of particles in healthy and diseased lungs, using radiolabeled aerosols and scintigraphic imaging assessments. This approach can be very useful in the development of aerosol therapies for treating patients with asthma, cystic fibrosis, lung transplant and diabetes and for answering basic physiologic questions about mucociliary clearance, a major lung defense mechanism. More recently, Dr. Laube has begun to apply this approach to improve delivery of aerosolized drugs to the nasal cavity and the sinuses. Dr. Laube has published over 50 peer-reviewed articles.
Best Oral Presentation
	Katharina Schwarz studied process engineering at the Technical University in Freiberg, Germany and graduated in 2007. During an internship and the diploma thesis in the Department of Aerosol Technology at the Fraunhofer Institute for Toxicology and Experimental Medicine she gained profound experience in the field of aerosol science. She worked on size-selective sampling of bio-aerosols and a technique for the generation of a calibration aerosol. Currently she is completing her PhD at the Fraunhofer ITEM, where, in close cooperation with clinicians of the Department of Clinical Airway Research, she is working on a multidisciplinary research project on non-invasive diagnostics of lung diseases using exhaled aerosols. Her extensive studies on physical properties of breath particles from healthy and diseased subjects contribute significantly toward the understanding of the process of endogenous aerosol generation and transport in the human lung. The results create the basis for the development of exhaled breath analysis as a potential tool for detection and monitoring of airway diseases. One important finding was that the exhaled particle size distribution pattern is different between healthy non-smokers, smokers and subjects with COPD. Her future work involves the further validation of breath analysis as diagnostic tool for early detection of lung diseases as well as for other fields of application.
ISAM AWARDS 2010
Thomas T. Mercer Award (jointly sponsored with AAAR)
	Wolfgang G. Kreyling is a biophysicist coordinating all aerosol-related research within the Focus Network Nanoparticles and Health of the Helmholtz Center Munich (HMGU, formerly GSF Research Center) spanning R&D work over five HMGU-institutes ranging from material sciences to toxicology and epidemiology. He is deputy director of the HMGU Comprehensive Pneumology Center, Institute of Lung Biology and Disease. He chairs the R&D program on dosimetry of ultrafine aerosol particles and engineered nanoparticles in the respiratory tract and secondary target organs like the cardiovascular and the central nervous system. His research interests range from aerosol sciences and nanoparticle technology to biophysics of the lungs reaching from the characterization of ambient aerosols to particle dosimetry and nanoparticle lung interactions on the level of the entire organism, cells like alveolar macrophages, and molecular compounds. He currently participates in four EU-FP7 funded projects and a German Research Foundation (DFG) funded consortium on interactions of engineered nanoparticles with biological systems and the safe and sustainable use of nanoparticles. In recent years Dr. Kreyling was President of the International Society for Aerosols in Medicine (ISAM). He is member of various other international scientific societies, serves as a member of several expert panels of European and German committees and he is editorial board member of several international aerosol and nanotechnology related journals.
ISAM AWARDS 2009 Awarded at the 17th International Congress in Monterey, USA
Career Achievement Award
	Myrna Dolovich is an Associate Clinical Professor of Medicine in the Faculty of Health Sciences, McMaster University, Hamilton, Ontario. She received her Bachelors Degree in Electrical Engineering from McGill University in 1963 and worked initially in the Cardio-Respiratory Department at the Royal Victoria Hospital with Dr. Joseph Milic-Emili, investigating ventilation-perfusion relationships in man. She joined McMaster University in 1968, Her research at Firestone Institute of Respiratory Health at McMaster involves investigations into the behaviour of therapeutic aerosols in the lung, with special interest in the measurement of lung deposition and distribution in patients with asthma and COPD, using both 2D and 3D imaging techniques. Current work also involves the determination of the function of epithelial cell cilia in COPD. She was involved in the design and characterization of the AerochamberR, a holding chamber spacer device for pMDIs used worldwide by patients with respiratory disease. She has published 140 book chapters and peer-reviewed papers in the medical literature and has spoken extensively on pulmonary drug delivery systems and imaging. She also currently serves as Chair of the Canadian Standards Association (CSA) Technical Sub-Committee that prepared the national standard for spacers and other drug delivery devices and is Head of the Canadian Delegation to the Canadian Advisory Council for the ISO Technical Committee 84 dealing with standards for drug delivery devices. She served on the Board of Directors of the International Society for Aerosols in Medicine (ISAM) and is a member of the Editorial Boards of the Journal of Aerosols in Medicine and Pediatric Allergy, Asthma and Immunology. In 2006, she was awarded the Thomas T Mercer Prize. Myrna continues her contributions to medical aerosol research at McMaster University in the Firestone Research Aerosol Laboratory located at St Joseph’s Healthcare in Hamilton.
Thomas T. Mercer Award (jointly sponsored with AAAR)
	Dieter Koehler (born 1948), professor of medicine is currently director of the Fachkrankenhaus Kloster Grafschaft, a hospital with subdivisions in internal medicine, intensive care medicine, pulmonology and allergology in Schmallenberg, Germany. He received as bachelor degree in electronic engeneering (1970) in Giessen and worked for the next two years in the electronic industry. Dieter Koehler completed his medical training at the University of Freiburg where he graduated in 1978. He received his PhD after completion of a residency in internal medicine and a fellowship in pneumonology and allergology in 1985. His research was focused on aerosol deposition and bronchial clearance. He is a member of the faculty of the University of Freiburg since 1985. In 1986 he became director of the Fachkrankenhaus Kloster Grafschaft. In 1992 he was awarded a professorship in internal medicine. He was vice chairman and chairman (1982-86) of the Imaging-section of the European Respiratory Society and served as the chairman of the congress of aerosol medicine and pneumology in Grafschaft 1987, 1989 and 1992. In 2003 he was elected vice president of the German society for pulmonology for the period 2005 - 2008. In 2005 he became president of the German society of allied chest clinics. Currently he is involved in research and publications about lung deposition, transport and elimination of aerosols ; inhalation therapy; labelling techniques of aerosols, biopsy techniques, sleep disorders, hypercapnic respiratory failure and weaning from mechanical ventilation.
Young Investigator Award
	PD Dr. Barbara Rothen-Rutishauser is leader of a research group in the Institute for Anatomy at the University of Bern, in Bern, Switzerland. She has received her Ph.D. in 1996 in cell biology at the Swiss Federal Institute of Technology (ETH) in Zurich. From 1996 to 2000 she held a post-doctoral position in Biopharmacy at the Institute of Pharmaceutical Sciences at the ETH where she developed and characterised cell culture models for drug transport studies. In 2000 she joined Prof. Peter Gehr’s research group where she started to investigate the mechanisms of particle-lung interactions. She has developed cell culture models to study the interaction of fine particles and nanoparticles with different types of lung cells. The main focus of her work is based on a triple cell co-culture system which simulates the respiratory tract wall. This system consists of alveolar or bronchial epithelial cells, macrophages and dendritic cells. The cells can be exposed to particles in suspension or at the air-interface to different types of nanoparticles. Particle-cell interactions, cell-cell interactions and cellular effects are then quantitatively examined with confocal laser scanning and transmission electron microscopy.
Student Research Award
	Shayna McGill received her B.Sc. from the University of Hawaii at Hilo in 2006. She is completing her PhD in the group of Prof. Hugh Smyth in the Division of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico. The group is interested in translating advances in material science and pharmaceutical engineering to target therapeutic molecules to a biological site of action within the lungs. Shayna McGill’s thesis focused on developing an understanding of the mechanisms by which superparamagnetic iron oxide nanoparticles (SPIONs) could enhance drug delivery through extracellular barriers within the lung. She has shown that these delivery systems can be pulled under a magnetic field through in vitro models of alginate biofilms at significantly enhanced rates compared to particles under no magnetic field. Additionally, under an oscillating magnetic field, SPIONs were able to increase diffusive transport of additional nanoparticles by disrupting DNA, used as a model of an extracellular barrier. In continuing her PhD work, Shayna McGill is formulating SPIONs into microparticles for aerosol therapy and evaluating the interactions these particles have with alginate biofilms and mucus. vaccination.
Juraj Ferin Award (for outstanding contributions to ISAM)
	Dr. Oberdörster earned his D.V.M. and Ph.D. (Pharmacology) from the University of Giessen in Germany and is Professor in the Department of Environmental Medicine at the University of Rochester, Director of the University of Rochester Ultrafine Particle Center, PI of a Multidisciplinary Research Initiative in Nanotoxicology and Head of the Pulmonary Core of the NIEHS Center Grant. His research includes the effects and underlying mechanisms of lung injury induced by inhaled non-fibrous and fibrous particles, including extrapolation modeling and risk assessment. His studies with ultrafine particles influenced the field of inhalation toxicology, raising awareness of the unique biokinetics and toxicological potential of nano-sized particles.
Best Oral Presentation
	Jennifer Burchell received her BSc (Honours) in Biomedical Science from Murdoch University, Perth, Western Australia in 2002. She then spent two years travelling and working in Europe where she spent 5 months in the laboratory of Prof. Bart Lambrecht at Erasmus Medical Centre, Rotterdam, The Netherlands to help establish the FlexiVent low-frequency forced oscillation technique and learn new immunological skills. Upon her return to Perth she commenced a PhD investigating the interplay between physiology and immunology in airway hyperresponsiveness, specifically the role of Regulatory T cells and Dendritic Cells in the attenuation of allergen-induced airway hyperresponsiveness. Jennifer was supervised by Prof. Peter Sly at Telethon Institute for Child Health Research, Perth, West Australia and the University of Western Australia. She successfully completed her PhD in 2008 and then spent 4 months undertaking volunteer work at Tilganga Eye Hospital in Kathmandu, Nepal to document the challenges of various eye surgeries used in developing countries. Jennifer is currently working as a postdoctoral scientist in the School of Paediatrics, University of Western Australia under the supervision of Dr. Sunalene Devadason. Her research goal is to combine her expertise in immunology and physiology of lung disease with clinical aerosol research.
ISAM AWARDS 2008
Thomas T. Mercer Award (jointly sponsored with AAAR)
	Warren Finlay is a Professor of Mechanical Engineering at the University of Alberta and the founding Director of the Aerosol Research Laboratory of Alberta (ARLA). He obtained M. Sc. (1984) and B. Sc. (1983) degrees in Electrical Engineering (Engineering Physics) from the University of Alberta and a Ph.D. in Mechanical Engineering from Stanford University (1987). He joined the University of Alberta as an Assistant Professor in 1987, and was promoted to the rank of Associate Professor in 1990 and full Professor in 1993. He has published over 100 highly respected journal articles on pharmaceutical aerosols, as well as more traditional engineering fields, and is an Editor of Aerosol Science and Technology. He has taught widely at the University of Alberta at both the undergraduate and graduate levels in Engineering, Pharmacy and Medicine. He is the author of a book entitled "The Mechanics of Inhaled Pharmaceuticals Aerosols: An Introduction", published by Academic Press, and is the recipient of various academic awards for outstanding achievement in addition to the Thomas T. Mercer prize, including the Alberta Summit Research Excellence Award, a Killam Annual Professorship, 1st prize at the Association of Health Technologies Industry 7th Innovation Research Contest, the Young Investigators Award from the International Society for Aerosols in Medicine, a McCalla Research Professorship and the Birks Gold Medal in Engineering, among others. He leads an outstanding team of students engaged in aerosol research at the University of Alberta and works extensively with companies around the world on drug delivery to the lung.
ISAM AWARDS 2007 Awarded at the 16th International Congress, Tours, France
Career Achievement Award
	Dr. Gerald Smaldone is a Professor of Medicine, Physiology and Biophysics at the State University of New York at Stony Brook. He received a Bachelors Degree in Chemical Engineering at New York University School of Engineering in 1969. In 1975, he completed a combined M.D., Ph.D. Program under the tutelage of Edward H. Bergofsky, M.D. at New York University School of Medicine. His thesis was in pulmonary mechanics. Dr. Smaldone received his clinical training as an intern and resident in the medicine program at The University of Rochester, New York, Strong Memorial Hospital. Between 1977 and 1980 he completed fellowships in Pulmonary Medicine and Environmental Physiology at The Johns Hopkins University. Since 1980, he has been at Stony Brook as a member of the Pulmonary/Critical Care Division, Department of Medicine. In 1996 he became Division Head. His research activities include a long-standing interest in pulmonary mechanics, the use of aerosols as special tools to study respiratory behavior and the development of better techniques for aerosolized drug delivery. Presently, he is actively involved in multiple projects utilizing monodisperse and polydisperse aerosols directed towards the study of inflammatory airway disease, airway geometry and drug delivery. In addition to his research activities, Dr. Smaldone actively practices at University Hospital. He specializes in pulmonary and critical care medicine. He is also the founding editor of the Journal of Aerosol Medicine.
Thomas T. Mercer Award (jointly sponsored with AAAR)
	Steve Newman is currently a Scientific Consultant based in Nottingham, UK. He holds a BA in Physics from the University of Oxford. In 1971 he joined the Department of Medical Physics at the Royal Free Hospital and School of Medicine, London, and from 1977 began research into inhaled drug delivery, leading to a PhD from the Faculty of Medicine in the University of London in 1982. He subsequently became a full-time member of the Department of Thoracic Medicine at the Royal Free Hospital and School of Medicine, where he developed his interest in pulmonary and nasal drug delivery for both local and systemic applications, with emphasis on inhaler devices and their assessment by in vitro and in vivo techniques. From 1991 to 2004, Steve was a Director of Pharmaceutical Profiles, a company based in Nottingham, UK, that uses radionuclide imaging in vivo to assess delivery of pharmaceutical dosage forms. Steve is a Fellow of the Institute of Physics and Engineering in Medicine (FIPEM), and also a Fellow of the Institute of Physics (FinstP). He has published over 220 research papers, invited articles and book chapters. He has given numerous lectures, both at international conferences, and within the pharmaceutical and medical communities, and is a member of the editorial boards of several journals.
Young Investigator Award
	Tim Corcoran is a Research Assistant Professor of Medicine at the University of Pittsburgh. He also holds secondary appointments in the Departments of Bioengineering and Chemical Engineering at the University of Pittsburgh, and in Biomedical Engineering at Carnegie Mellon University. He received his B.S. and M.S. degrees in Mechanical Engineering from Lehigh University in 1990 and 1992. He received a Ph.D. in Biomedical Engineering from Carnegie Mellon University in 2000. His past research interests have included the development of inhaled medications for lung transplant recipients and patients with cystic fibrosis. This work has included in vitro studies of aerosol drug delivery systems, the performance of radioscintigraphy deposition studies, and the development of adjuncts to improve drug delivery. More recently he has become involved in the performance of mucociliary clearance studies and the development of new aerosol-based outcome measurements for use in clinical studies of cystic fibrosis.
Student Research Award
	Antoine Minne received his PharmD from the Université catholique de Louvain in 2003. He is completing his PhD in the group of Prof. Rita Vanbever at the division of Pharmaceutical Technology, School of Pharmacy, Université catholique de Louvain, Belgium. The group is interested in the optimization of inhalation aerosols for systemic absorption of therapeutic proteins and peptides, as well as in the pulmonary delivery of vaccines as an alternative to injection. Antoine Minne worked on the development of an inhaled influenza vaccine. He showed that delivery of the vaccine to the deep lung induced the broadest and most intense immune response over other respiratory tract regions and i.m. injection. Moreover, pulmonary administration was safe as it did not induce significant acute or chronic lung inflammation in healthy animals and did not exacerbate the asthmatic condition of allergen-sensitized animals. The continuation of Antoine Minne’s PhD work involved the formulation of a spray-dried carrier powder with optimal physico-chemical and aerodynamic properties and the assessment of its deposition pattern within the respiratory tract of mice. Finally, he showed that the excipients used in the dry-powder formulation might adjuvant pulmonary influenza vaccination.
Juraj Ferin Award (for outstanding contributions to ISAM)
	Wolfgang G. Kreyling is a biophysicist coordinating all aerosol-related research within the GSF Focus Network Aerosols and Health spanning R&D work over five GSF-institutes ranging from material sciences to toxicology and epidemiology. He is deputy director of the GSF-Institute for Inhalation Biology. His research interests range from aerosol sciences and nanoparticle technology to biophysics of the lungs reaching from the characterization of ambient aerosols to particle dosimetry and nanoparticle lung interactions on the level of the entire organism, cells like alveolar macrophages, and molecular compounds. Using his quantitative biokinetics rodent model he recently demonstrated that the biokinetics and accumulation of nanoparticles in secondary target organs like liver, kidneys, brain, heart and reproductive organs depends strongly on their properties such as size and surface ligands. He received his Ph.D. at the Technical University of Munich. In 1985/86 he spent a sabbatical at the Harvard School of Public Health in Boston, MA, USA. He holds more than 150 peer-reviewed publications in international journals and books. As early as 1983 he became interested in ISAM and served in several functions including a 12-years-service within the board of ISAM.
Best Oral Presentation
	Michael Bur studied pharmacy at the Saarland University, Germany and graduated in 2003. His diploma thesis was about ion fluxes across tight cell monolayers of primary alveolar cells. Currently he is doing his PhD in the group of Prof. Claus-Michael Lehr at the department of biopharmacy and pharmaceutical technology, Saarland University. The topic of his research is cell compatible drug deposition and absorption models which mimic the aerosol properties as well as the situation on the human air-blood-barrier. Mainly human alveolar primary cells cultivated on an air interface are used as model of the human air blood barrier. Deposition of medical aerosols is conducted with size separating by a cell compatible multi stage liquid impinger or without size separation with the aid of an insufflator syringe. Influences of particles size, fluid volume on the cell monolayer, and wettability of the applied aerosol formulations are investigated. Michael Bur’s work is supported in parts by the Federal Ministry of Education and Research, Project: NanoInhale (13N8890).